Ontology highlight
ABSTRACT: Objective
The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. Label-retaining cancer cells (LRCC) represent a novel subpopulation of cancer stem cells (CSC). The objective was to test whether LRCC are resistant to sorafenib.Methods
We tested human HCC derived LRCC and non-LRCC before and after treatment with sorafenib.Results
LRCC derived from human HCC are relatively resistant to sorafenib. The proportion of LRCC in HCC cell lines is increased after sorafenib while the general population of cancer cells undergoes growth suppression. We show that LRCC demonstrate improved viability and toxicity profiles, and reduced apoptosis, over non-LRCC. We show that after treatment w
SUBMITTER: Xin HW
PROVIDER: S-EPMC6993136 | biostudies-literature | 2013 Dec
REPOSITORIES: biostudies-literature